ARCT
NASDAQ
US
Arcturus Therapeutics Holdings Inc. - Common Stock
$8.03
▲ +$0.18
(+2.29%)
Vol 506K
5
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$174.2M
ROE
-28.7%
Margin
-68.4%
D/E
0.00
Beta
2.38
52W
$6–$24
Wall Street Consensus
19 analysts · Apr 20265
Strong Buy
10
Buy
4
Hold
0
Sell
0
Strong Sell
78.9%
Buy Rating
Price Chart
Similar Stocks
RNA
Atrium Therapeutics Inc
$10.9B
ELDN
Eledon Pharmaceuticals Inc
$113.4M
CAMP
CAMP4 Therapeutics Corp
$318.0M
NERV
Minerva Neurosciences Inc
$28.1M
FENC
Fennec Pharmaceuticals Inc
$262.9M
KRRO
Korro Bio Inc
$75.4M
NVCT
Nuvectis Pharma Inc
$193.4M
ANIK
Anika Therapeutics Inc
$138.6M
SABS
SAB Biotherapeutics Inc
P/E 9.5
$178.0M
About Arcturus Therapeutics Holdings Inc. - Common Stock
Arcturus Therapeutics (ARCT) — біотехнологічна компанія, що спеціалізується на розробці мРНК-вакцин і терапії. Вони використовують власну технологію доставки ліків LUNAR для створення інноваційних препаратів. Arcturus займає нішу на ринку мРНК-технологій, маючи конкурентну перевагу у власній платформі доставки та зосередженні на рідкісних захворюваннях.
Earnings
Beat rate: 75.0%
Next Report
May 11, 2026
EPS Estimate: $-1.10
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-1.10 | — | — |
| Dec 2025 | $-0.73 | $-1.03 | $-0.30 |
| Sep 2025 | $-0.84 | $-0.49 | +$0.35 |
| Jun 2025 | $-0.91 | $-0.34 | +$0.57 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -24.9% | -24.9% | -24.9% | -24.9% | -28.7% | -28.7% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -32.4% | -49.3% | -49.3% | -49.3% | -68.3% | -68.3% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 5.90 | 5.90 | 5.90 | 5.90 | 7.86 | 7.86 |
Key Ratios
ROA (TTM)
-21.1%
P/S (TTM)
1.78
P/B
1.9
EPS (TTM)
$-2.46
CF/Share
$3.73
Rev Growth 3Y
+130.7%
52W High
$24.17
52W Low
$5.85
$5.85
52-Week Range
$24.17
How does ARCT compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
ARCT valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
1.8
▼
86%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
1.9
▼
22%
below
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
ARCT profitability vs Biotechnology peers
ROE
-28.7%
▲
57%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
-68.4%
▲
76%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-21.1%
▲
55%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
ARCT financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
7.9
▲
77%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
2.4
▲
146%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
ARCT fundamentals radar
ARCT
Peer median
Industry
ARCT profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio